This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ironwood Pharmaceuticals Details Strategy To Establish Leading Gastrointestinal Therapeutics Company

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will detail its strategy to establish a leading gastrointestinal (GI) therapeutics company during its Investor Day today in New York City. This strategy leverages Ironwood’s strong development and commercial capabilities in addressing GI disorders as well as its pharmacologic expertise in guanylate cyclase (GC) pathways, all of which is based on Ironwood’s pioneering work bringing forward LINZESS, the first FDA-approved product in a new class of GI medicines called GC-C agonists.

“At Ironwood, we’ve had the privilege to successfully discover, develop and commercialize LINZESS, a medicine that is already helping hundreds of thousands of adult patients suffering from IBS-C or CIC. Our commercial and R&D teams are both executing at a very high level: we are working closely with our U.S. partner Forest to drive strong uptake of LINZESS, and we are also building a robust pipeline of potential treatments for other highly symptomatic GI conditions,” said Peter Hecht, chief executive officer of Ironwood Pharmaceuticals, Inc. “With LINZESS well on its way to becoming a leading GI brand, we have both the opportunity and the obligation to prioritize the areas of our business that we believe will maximize value for patients and shareholders. We will leverage our development and commercial expertise in an effort to address patient needs across the upper and lower gastrointestinal tract, and we will build on our deep pharmacologic expertise as we work to unlock value from our GC research platform, with a goal of advancing seven GI clinical development programs with multiple opportunities to generate proof of concept data over the next 24 months.”

To execute on its strategy, Ironwood will:
  • Maximize LINZESS
  • Leverage strong commercial capabilities
  • Advance robust GI pipeline and guanylate cyclase (GC) research
  • Prioritize investments in key value drivers

Maximize LINZESS

Ironwood and Forest Laboratories, Inc. introduced LINZESS in December 2012 for the treatment of adult patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). In its first year on the market, LINZESS has delivered strong results across key leading indicators for commercial success, including physician adoption and prescription rates, payer uptake and patient persistency.

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,619.51 +23.16 0.13%
S&P 500 2,063.12 +5.48 0.27%
NASDAQ 4,986.8670 +28.3990 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs